TD Waterhouse Canada Inc. Sells 16,903 Shares of IQVIA Holdings Inc. $IQV

TD Waterhouse Canada Inc. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 98.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 206 shares of the medical research company’s stock after selling 16,903 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in IQVIA were worth $42,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Artisan Partners Limited Partnership bought a new position in shares of IQVIA in the 2nd quarter worth approximately $515,772,000. Norges Bank purchased a new position in shares of IQVIA in the 2nd quarter worth about $270,160,000. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC lifted its position in IQVIA by 15,755.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after acquiring an additional 774,681 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after buying an additional 606,391 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research reports. Barclays set a $210.00 target price on shares of IQVIA in a report on Friday. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Evercore ISI reiterated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research note on Thursday. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Finally, Mizuho set a $266.00 price objective on IQVIA in a research report on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $248.88.

Key Headlines Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus — EPS of $3.42 and revenue of $4.36B, with double‑digit year‑over‑year sales growth and strong segment performance. These beats confirm demand improvement from pharma clients. Read More.
• Positive Sentiment: Company provided FY‑2026 guidance (EPS 12.55–12.85; revenue ~$17.2–17.4B) that includes revenue growth expectations above some street estimates — this supports top‑line momentum if execution continues. Read More.
• Neutral Sentiment: Market takeaways from the quarter are mixed: strong near‑term results but mixed messaging on margins and expense drivers; investors are parsing detail in the call and slides. Read More.
• Negative Sentiment: Management flagged higher interest costs that push 2026 profit expectations below some Street forecasts — this hit the stock because financing costs directly compress EPS despite revenue strength. Read More.
• Negative Sentiment: Headline guidance/adjusted‑earnings outlook was viewed as a miss by some investors and commentators, prompting downside pressure immediately after results. Read More.
• Negative Sentiment: Analysts are questioning how quickly IQVIA’s AI initiatives will translate into meaningful revenue or margin gains, increasing near‑term uncertainty around growth assumptions. Read More.
• Negative Sentiment: Some firms are trimming ratings amid sector headwinds and the mixed outlook, further pressuring sentiment. Read More.
• Negative Sentiment: Market commentary summarizing these factors is driving intraday selling and positioning adjustments. Read More.

IQVIA Trading Down 10.8%

Shares of IQV opened at $180.62 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a market cap of $30.76 billion, a P/E ratio of 24.78, a P/E/G ratio of 2.06 and a beta of 1.37. The company’s fifty day simple moving average is $228.83 and its 200-day simple moving average is $209.42.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the previous year, the business earned $3.12 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.